TransCode Therapeutics (RNAZ)

Executive Summary

TransCode Therapeutics is a clinical-stage biopharmaceutical company developing RNA-based therapies for metastatic cancer. Its lead candidate, TTX-MC138, targets microRNA-10b, a master regulator of metastasis, using a proprietary iron oxide nanoparticle delivery platform. The company aims to address the significant unmet need in metastatic disease across multiple cancer types. Founded in 2016 and headquartered in Boston, TransCode went public in 2021 and trades under the ticker RNAZ. Despite a challenging financing environment, the company has advanced TTX-MC138 into Phase 1 clinical trials, positioning it as a potential first-in-class anti-metastatic therapy. TransCode's clinical focus is on demonstrating safety and preliminary efficacy in patients with advanced solid tumors known to overexpress microRNA-10b. The nanoparticle platform offers unique advantages in RNA delivery, potentially overcoming key barriers in the field. However, as a micro-cap public company, TransCode faces significant financial and execution risks. Success hinges on positive clinical data, regulatory engagement, and securing additional capital. If successful, TTX-MC138 could transform the treatment landscape for metastatic disease, representing a multi-billion-dollar opportunity. Near-term catalysts include initial Phase 1 data and potential regulatory designations.

Upcoming Catalysts (preview)

• H2 2026Phase 1 interim safety and efficacy data for TTX-MC13835% success
• Q3 2026FDA regulatory designation (e.g., Fast Track) for TTX-MC13850% success
• Q4 2026Preclinical data on next-generation nanoparticle platform40% success